Quantcast

Former Imprimis Pharmaceuticals subsidiary Eton Pharmaceuticals increases proposed IPO deal size


Shutterstock photo

Eton Pharmaceuticals, which is developing liquid formulations of various approved drugs, raised the proposed deal size for its upcoming IPO on Monday.

The Deer Park, IL-based company now plans to raise $22 million by offering 3.6 million shares at a price of $6. The company had previously filed to offer 3 million shares at the same price. At $6, Eton Pharmaceuticals will raise 20% more in proceeds than previously anticipated.

Eton Pharmaceuticals was founded in 2017 and plans to list on the Nasdaq under the symbol ETON. National Securities is the sole bookrunner on the deal. 

The article Former Imprimis Pharmaceuticals subsidiary Eton Pharmaceuticals increases proposed IPO deal size originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs










Research Brokers before you trade

Want to trade FX?